While TGF-β signaling is known to promote myofibroblast differentiation, targeting this pathway in cancer is problematic because it also regulates tumor-suppressive functions, and ubiquitous inhibition has been shown to result in the development of cutaneous keratoacanthomas/squamous cell carcinomas (43,44). The gene discussed is TGFB1; the disease is neoplasm.